Navigation Links
Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
Date:6/2/2008

ation," said Daniel Haller, M.D., Professor of Medicine at the Abramson Cancer Center at the University of Pennsylvania. "This novel oncolytic, NKTR-102, could offer an alternative and promising approach for tumors in this patient population."

The company also announced new trials for NKTR-102 in breast and ovarian cancer. These studies will be open-label, single-arm studies to evaluate the overall response rate (ORR) of NKTR-102 monotherapy in each tumor setting. The studies will implement a minimax design, known as the Simon design, which was first proposed by Dr. Richard Simon of the National Cancer Institute in 1989. The two-stage design is routinely used in the evaluation of oncolytics.(1)

"The promise of NKTR-102 and our small molecule PEGylation platform is capturing a great deal of attention among oncologists and clinical investigators," said Howard W. Robin, Nektar President and CEO. "We've seen significant and repeat anti-tumor activity in our Phase 1 study with NKTR-102. Our expanded Phase 2 clinical development plan will potentially accelerate our understanding and development of this novel therapy in multiple cancer types."

Details on the NKTR-102 Phase 2 clinical development plan will be discussed at an event on June 2, 2008 at 6:30 PM Central time. The event will be Webcast and can be accessed from the company's website at the following url: http://www.nektar.com/wt/page/asco.

About NKTR-102 (PEG-irinotecan)

Nektar is developing NKTR-102, a PEGylated form of irinotecan, which was invented by Nektar using its world-leading small molecule PEGylation technology platform. The product is currently in a Phase 2a study to evaluate NKTR-102 in combination with cetuximab.

Irinotecan is an important chemotherapeutic agent used for the treatment of solid tumors, including colorectal and lung cancers. By applying Nektar's small molecule PEGylation technology t
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 Sonic Innovations, Inc. (Sonic), a ... solutions, donated $10,000 to its local Feeding America ... 2009. ,, Sonic Innovations President Paul Wennerholm presented ... member, the Utah Food Bank, at the nonprofit ... participated in an office food drive and volunteered ...
(Date:12/15/2009)... KV Pharmaceutical Company ( KVa/KVb) today announced ... written notice (the "Notice") executed by the Marc S. ... Company, requesting that the Board of Directors of the ... action by written consent relating to the proposed appointment ... resulting from Ronald J. Kanterman,s departure (the "Director Appointment"). ...
(Date:12/15/2009)... Ever wonder what something looks like up ... of the Personal Scanning Electron Microscope (PSEM), kicked off ... send in samples to be scanned by one of ... scan range of 100nm to 5mm and an imaging ... into focus. In addition, ASPEX will not only scan ...
Breaking Medicine Technology:Sonic Innovations, Inc. Donates $10,000 to Feeding America 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 7ASPEX Kicks Off Free 'Send Us Your Sample' Microscopy Campaign 2Makers of Trojan 28R 29 Brand Condoms Introduce Trojan 2GO 28R 29 a Unique Portable Protective and Discreet Packaging for Condoms 58140 1Makers of Trojan 28R 29 Brand Condoms Introduce Trojan 2GO 28R 29 a Unique Portable Protective and Discreet Packaging for Condoms 58140 2Makers of Trojan 28R 29 Brand Condoms Introduce Trojan 2GO 28R 29 a Unique Portable Protective and Discreet Packaging for Condoms 58140 3Makers of Trojan 28R 29 Brand Condoms Introduce Trojan 2GO 28R 29 a Unique Portable Protective and Discreet Packaging for Condoms 58140 4CMHS 28dba Hybrid Energy Holdings 29 changes name of corporation and prepares to file for ticker symbol change with FINRA 58135 1CMHS 28dba Hybrid Energy Holdings 29 changes name of corporation and prepares to file for ticker symbol change with FINRA 58135 2Pittsburgh Life Sciences Greenhouse Demonstrates a Regions Economic Resilience 14229 1Pittsburgh Life Sciences Greenhouse Demonstrates a Regions Economic Resilience 14229 2Pittsburgh Life Sciences Greenhouse Demonstrates a Regions Economic Resilience 14229 3
... February 23 BN,ImmunoTherapeutics, Inc. today provided updated ... vaccine, MVA-BN(R)-HER2, in development as,therapy of metastatic breast ... its primary endpoint with regards to safety and ... immune response was,detected in approximately 70% of evaluated ...
... Diagnostics Inc. (TSX:SDI) today announced that it presented new ... Activity Assay, the only FDA cleared diagnostic for the ... for Endotoxemia congress. The conference took place in Tokyo, ... on the role of endotoxemia in sepsis. In addition ...
Other Medicine Technology:BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 2BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 3Spectral presents data on the clinical utility of EAA(TM) at 13th Annual Critical Care for Endotoxemia conference in Japan 2
(Date:12/16/2009)... QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - TSO3 Inc. ... that an agreement has been reached for 3M ... TSO3,s STERIZONE(R) 125L+ Sterilizer. The partnership with TSO3, ... medical devices in healthcare settings through the use ... acute care facilities through 3M,s global sales channel. ...
(Date:12/16/2009)... Medical Association’s Seal of Acceptance , ... ... continue their search for the perfect gift this season, many ... are considered healthy for the environment. When it comes to ... most stylish items are also healthy for feet—making a great ...
(Date:12/16/2009)... time it takes to obtain a bachelor degree, an individual ... , ... (Vocus) December 16, 2009 ... Report Card on Higher Education" by the National Center for ... outpaced price increases in other sectors of the economy.”¹ Since ...
(Date:12/16/2009)... announced a great addition to one of the most superior ... at www.hallmark.co.uk/specialoccasions , customers can now personalise just about any ... and then order as many copies of their design with the ... ... 16, 2009 -- Just in time for the Christmas rush Hallmark ...
(Date:12/16/2009)... be the perfect gift to give that special woman who has ... Licensed Esthetician Mary Schook introduces exceptional beauty products online while educating ... , ... (PRWEB) December 16, 2009 -- The holidays are ... that special woman who has everything? Why stem cells, of course!, ...
Breaking Medicine News(10 mins):Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 2Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 3Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 4Health News:Put Some "Green" Into Gift-Giving With Eco-Friendly Footwear Products 2Health News:Put Some "Green" Into Gift-Giving With Eco-Friendly Footwear Products 3Health News:Put Some "Green" Into Gift-Giving With Eco-Friendly Footwear Products 4Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 2Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 3Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 4Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 5Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 2Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 3Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 4Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2
... spread of certain cancers to lymph nodes often ... lymphatic system and can cause lymphedema, a condition ... to infections. , The researchers of the University ... Cancer Research show that application of vascular endothelial ...
... VANCOUVER, and SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ - ... of drugs for infectious,diseases, has received preliminary four-week ... in hepatitis C virus ("HCV") treatment-naive,patients which indicate ... no negative effects on the tolerability, pharmacokinetics,and viral ...
... 37 Hospitals Receive Funding To Implement Safety Initiatives, ... the number,of rural and public hospitals participating in ... Campaign, the Cardinal Health,Foundation announced today it is ... their data to IHI. Hospitals will receive an ...
... Base Surpasses 660 Sites, DENVER, Dec. ... Board: GLOB), an international e-Health, medical,information technology ... has signed an agreement to license its ... Hospital, of,Sheridan, Wyoming. Sheridan Memorial Hospital (Sheridan) ...
... programs can boost the bottom line for companies and their ... ... have begun implementing,wellness programs to curb rising health care costs and help ... Wellness programs -- which can include offerings from smoking cessation,plans and counseling ...
... global application software and services company, today announced that,United ... Innovation,solutions to support its expansion of business in Taiwan., ... Kong location since,2003, and have supported a period since ... UCB concluded to expand the use of both systems ...
Other Medicine News:Health News:Lymphatic vessel and lymph node function are restored with growth factor treatment 2Health News:Lymphatic vessel and lymph node function are restored with growth factor treatment 3Health News:MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study 2Health News:MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study 3Health News:MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study 4Health News:MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study 5Health News:MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study 6Health News:Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHI'S 5 Million Lives Campaign 2Health News:Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHI'S 5 Million Lives Campaign 3Health News:Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHI'S 5 Million Lives Campaign 4Health News:Global Med Technologies(R), Inc. Adds Wyoming Hospital to Growing Customer Base 2Health News:Global Med Technologies(R), Inc. Adds Wyoming Hospital to Growing Customer Base 3Health News:Employee Health Includes Financial Health, Too 2Health News:United Commercial Bank Extends its Use of Misys' Equation and Trade Innovation Systems to Support its Expansion in Taiwan 2Health News:United Commercial Bank Extends its Use of Misys' Equation and Trade Innovation Systems to Support its Expansion in Taiwan 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: